Immune Rejuvenation

Key Takeaways

Immunosenescence includes reduced naive T-cell output, altered immune memory, and weaker responses to some novel threats.
Inflammaging describes chronic, low-grade inflammatory signalling that is associated with multiple age-related diseases.
Thymic involution is a major research target, but evidence for clinically meaningful reversal in general ageing remains limited.
Engineered immune-cell approaches, including senolytic CAR-T models, are mostly preclinical in ageing contexts.

The Dual Burden: Immunosenescence and Inflammaging

The ageing immune system shows both reduced adaptive flexibility and increased inflammatory tone. Immunosenescence includes reduced naive T-cell production, clonal expansion of memory cells, and weaker responses to some infections and vaccines. Inflammaging refers to chronic, low-grade inflammatory signalling from innate immune cells, senescent cells, damaged tissues, and other sources. These patterns are studied as contributors to age-related disease, but reversing them safely is difficult because immune activation and immune suppression both carry risks.

These labels describe overlapping patterns rather than a single uniform state. Ageing can alter B cells, T cells, myeloid cells, natural killer cells, lymphoid organs, and tissue-resident immune populations in different ways. Persistent infections, recent illness, frailty, medication, and chronic disease can also influence the same measurements. Consequently, no single cytokine level or immune-cell count is a complete measure of immune age.

What Would Count as Rejuvenation?

A convincing intervention would do more than make an immune profile appear younger. It would improve a defined function, such as response to a new antigen, vaccine protection, infection control, or immune reconstitution, without producing excess inflammation, autoimmunity, or impaired tumour surveillance. Studies should distinguish increased cell numbers from greater receptor diversity and effective cell function. They should also show how long a change persists, because short-term mobilization of cells into blood may not represent durable repair of the immune system or its tissue niches.

Reversing Thymic Involution

The thymus is the anatomical site of T-cell maturation. In humans, thymic involution begins early in life and continues with age: functional epithelial space contracts, adipose tissue accumulates, and naive T-cell output declines. The pace and degree of these changes vary among individuals, and measurable thymic activity can persist into later life.^[3]

Several avenues are being studied in relation to thymic involution:

Recombinant cytokines and growth factors: Small human studies, including TRIIM, have examined combinations such as recombinant human growth hormone, DHEA, and metformin. Findings are preliminary and require larger controlled replication.
Senescent-cell targeting: Clearing senescent cells from immune niches is a plausible mechanism under study, but thymus-specific evidence remains early.
Keratinocyte growth factor (KGF): KGF has clinical use in specific oncology-support settings and is studied for effects on thymic epithelial cells, but this is not evidence of a general anti-ageing therapy.

Engineered Senolytic Interventions: CAR-T Cells

CAR-T cells are engineered immune cells designed to recognize specific surface markers. In ageing research, one experimental idea is to target markers enriched on senescent cells, such as uPAR. This approach could in principle improve selectivity compared with broadly acting small molecules, but marker specificity, tissue distribution, persistence, and safety are unresolved.

In 2020, Amor et al. reported that uPAR-targeted CAR-T cells cleared senescent cells and improved outcomes in mouse models of lung cancer and liver fibrosis. This is an important proof-of-concept, but it does not establish broad senescent-cell clearance as safe or effective for human ageing.

Later work in naturally aged mice reported improvements in exercise capacity and metabolic measures after uPAR-targeted CAR-T treatment.^[4] The result extends the animal proof-of-concept but remains preclinical. uPAR is not exclusive to senescent cells, senescent states vary by tissue and cause, and some senescent cells participate in wound repair. Human translation would require careful target validation, dose control, surveillance for off-target injury, and evidence that a functional gain outweighs the risks of a persistent engineered-cell therapy.

Challenges in Application

Immune therapies can carry serious risks. Cytokine release syndrome is a known complication of some cell therapies, and immune modulation can also increase infection, autoimmunity, or malignancy risk depending on context. Because immune ageing is system-wide and heterogeneous, studies need to separate short-term biomarker changes from durable clinical benefit.

References

Fahy, G. M. et al. "Reversal of epigenetic aging and immunosenescent trends in humans." Aging Cell (2019). https://doi.org/10.1111/acel.13028
Amor, C. et al. "Senolytic CAR T cells reverse senescence-associated pathologies." Nature (2020). https://doi.org/10.1038/s41586-020-2403-9
Liang, Z., Dong, X., Zhang, Z., Zhang, Q., & Zhao, Y. (2022). Age-related thymic involution: mechanisms and functional impact. Aging Cell, 21(8), e13671. https://pubmed.ncbi.nlm.nih.gov/35822239/
Amor, C. et al. "Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction." Nature Aging (2024). https://doi.org/10.1038/s43587-023-00560-5

Educational Disclaimer

This content is provided for academic reference only and does not constitute advice. Experimental immunotherapy models discussed here are largely limited to preclinical trials.